Antiviral therapy of HCV in the cirrhotic and transplant candidate

<p>Despite the improved efficacy of peginterferons, the rate of sustained virologic response is suboptimal in cirrhotic patients, relative to non-cirrhotic patients. However, the treatment of patients with compensated cirrhosis has recently been encouraged by expert panels. Interferon-based th...

Full description

Bibliographic Details
Format: Article
Language:English
Published: Ivyspring International Publisher 2006-04-01
Series:International Journal of Medical Sciences
Subjects:
Online Access:http://www.medsci.org/v03p0075.htm
id doaj-88e8ea5198b848a6809218bba6008778
record_format Article
spelling doaj-88e8ea5198b848a6809218bba60087782020-11-25T01:05:49ZengIvyspring International PublisherInternational Journal of Medical Sciences1449-19072006-04-01327578Antiviral therapy of HCV in the cirrhotic and transplant candidate<p>Despite the improved efficacy of peginterferons, the rate of sustained virologic response is suboptimal in cirrhotic patients, relative to non-cirrhotic patients. However, the treatment of patients with compensated cirrhosis has recently been encouraged by expert panels. Interferon-based therapy may provide additional benefit by reducing the risk of hepatocellular carcinoma in cirrhotic patients as suggested in preliminary studies. Results of two ongoing prospective studies are awaited to answer the important question of the effectiveness of suppressive interferon therapy, even in the absence of sustained virologic response. Given the importance of recurrent HCV following liver transplantation, attention has been directed toward the antiviral treatment of patients with advanced liver disease. This approach needs to be pursued with caution given the potential morbidity of the therapy. Recently, a low accelerating dosage regimen has provided excellent results and is the subject of additional inquiry.</p>http://www.medsci.org/v03p0075.htmhepatitis C viruscirrhosisliver transplantationantiviral therapy
collection DOAJ
language English
format Article
sources DOAJ
title Antiviral therapy of HCV in the cirrhotic and transplant candidate
spellingShingle Antiviral therapy of HCV in the cirrhotic and transplant candidate
International Journal of Medical Sciences
hepatitis C virus
cirrhosis
liver transplantation
antiviral therapy
title_short Antiviral therapy of HCV in the cirrhotic and transplant candidate
title_full Antiviral therapy of HCV in the cirrhotic and transplant candidate
title_fullStr Antiviral therapy of HCV in the cirrhotic and transplant candidate
title_full_unstemmed Antiviral therapy of HCV in the cirrhotic and transplant candidate
title_sort antiviral therapy of hcv in the cirrhotic and transplant candidate
publisher Ivyspring International Publisher
series International Journal of Medical Sciences
issn 1449-1907
publishDate 2006-04-01
description <p>Despite the improved efficacy of peginterferons, the rate of sustained virologic response is suboptimal in cirrhotic patients, relative to non-cirrhotic patients. However, the treatment of patients with compensated cirrhosis has recently been encouraged by expert panels. Interferon-based therapy may provide additional benefit by reducing the risk of hepatocellular carcinoma in cirrhotic patients as suggested in preliminary studies. Results of two ongoing prospective studies are awaited to answer the important question of the effectiveness of suppressive interferon therapy, even in the absence of sustained virologic response. Given the importance of recurrent HCV following liver transplantation, attention has been directed toward the antiviral treatment of patients with advanced liver disease. This approach needs to be pursued with caution given the potential morbidity of the therapy. Recently, a low accelerating dosage regimen has provided excellent results and is the subject of additional inquiry.</p>
topic hepatitis C virus
cirrhosis
liver transplantation
antiviral therapy
url http://www.medsci.org/v03p0075.htm
_version_ 1725192966630277120